InflaRx N.V. (FRA:IF0)

Market Cap	205.30M +177.1%
Revenue (ttm)	-10.10K -82.3%
Net Income	-39.14M
EPS	-0.49
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,900
Open	1.380
Previous Close	1.370
Day's Range	1.280 - 1.380
52-Week Range	0.663 - 2.456
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 6, 2026

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its u...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 65
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: IF0

Financial Performance

In 2025, InflaRx's revenue was 29,331, a decrease of -82.31% compared to the previous year's 165,789. Losses were -45.63 million, -0.93% less than in 2024.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error